{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:49:57Z","timestamp":1767134997438,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd009730.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000}}],"reference-count":283,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009730.pub3","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T06:48:53Z","timestamp":1737355733000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis"],"prefix":"10.1002","volume":"2025","author":[{"given":"Matthew N","family":"Hurley","sequence":"additional","affiliation":[{"name":"Paediatric Respiratory Medicine, Nottingham Children's Hospital; Nottingham University Hospitals NHS Trust; Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherie","family":"Smith","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health, School of Medicine; University of Nottingham; Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Flume","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Pulmonary and Critical Care; Medical University of South Carolina; Charleston South Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikki","family":"Jahnke","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health, School of Medicine; University of Nottingham; Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P","family":"Prayle","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health, School of Medicine; University of Nottingham; Nottingham UK"},{"name":"NIHR Biomedical Research Centre; University of Nottingham; Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD009730.pub3-BIB0001|cit1","first-page":"671","article-title":"Alternative antibiotics against Pseudomonas infections in cystic fibrosis. In vitro activity, pharmacokinetics, and double-blind randomized clinical trial with azlocillin, piperacillin, cefoperazone, ceftazidime, cefsulodin, cefotaxime and moxalactam. Preliminary results","volume":"98","author":"Agostini","year":"1983","journal-title":"Drugs under Experimental and Clinical Research"},{"issue":"Suppl A","key":"10.1002\/14651858.CD009730.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/jac\/12.suppl_A.297","article-title":"Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis","volume":"12","author":"Mastella","year":"1983","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0003|cit3","unstructured":"Aztreonam for inhalation for the treatment of acute exacerbations in cystic fibrosis. An open-label, randomised, cross-over pilot study of AZLI plus intravenous Colistin versus standard dual intravenous therapy www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2016-002832-34 2016"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0004|cit4","first-page":"A13","article-title":"Inhaled aztreonam lysine recovers lung function and improves quality of life in acute pulmonary exacerbations of cystic fibrosis","volume":"74","author":"Frost","year":"2019","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ppul.22495","article-title":"Aztreonam lysine inhalation solution recovers lung function and improves quality of life in treatment of acute pulmonary exacerbation of cystic fibrosis","volume":"54 Suppl 2","author":"Frost","year":"2019","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/S1569-1993(20)30485-9","article-title":"Aztreonam lysine recovers lung function and improves quality of life in the treatment of acute exacerbations of cystic fibrosis: results from an open-label randomised crossover study (AZTEC-CF)","volume":"19","author":"Frost","year":"2020","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl","key":"10.1002\/14651858.CD009730.pub3-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1016\/S1569-1993(20)30422-7","article-title":"Inhaled and intravenous treatment strategies exert different effects on the lung microbiome during acute pulmonary exacerbations of cystic fibrosis: results from the AZTEC-CF study","volume":"19","author":"Frost","year":"2020","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S2","key":"10.1002\/14651858.CD009730.pub3-BIB0008|cit8","first-page":"330","article-title":"Aztec-CF study: aztreonam lysine for inhalation in the treatment of pulmonary exacerbations of cystic fibrosis","volume":"53","author":"Frost","year":"2018","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD009730.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.jcf.2020.12.012","article-title":"The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: an open-label randomised crossover study (AZTEC-CF)","volume":"20","author":"Frost","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0010|cit10","unstructured":"Aztreonam for inhalation solution (AZLI) for the treatment of exacerbations of cystic fibrosis clinicaltrials.gov\/show\/NCT02894684"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0011|cit11","unstructured":"Black A Redmond A Scott E Randomised study comparing courses of oral ciprofloxacin alone with intermittent courses of intravenous azlocillin plus tobramycin or oral ciprofloxacin in the treatment of acute exacerbations of respiratory infection in cystic fibrosis 16th Annual Meeting of the European Working Group for Cystic Fibrosis; 1989; Prague, Czechoslovakia"},{"issue":"Suppl F","key":"10.1002\/14651858.CD009730.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/26.suppl_F.25","article-title":"Tolerance and safety of ciprofloxacin in paediatric patients","volume":"26","author":"Black","year":"1990","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0013|cit13","unstructured":"Black A Stevenson M Scott E Redmond A Randomised study comparing oral ciprofloxacin alone with ciprofloxacin alternating with intravenous therapy in cystic fibrosis 17th European Cystic Fibrosis Conference; 1991 Jun 18-21; Copenhagen, Denmark"},{"issue":"Suppl 25","key":"10.1002\/14651858.CD009730.pub3-BIB0014|cit14","first-page":"294","article-title":"Meropenem (MEM) compared with ceftazidime (CAZ) in combination with tobramycin (TOB) for treatment of acute pulmonary exacerbations (APE) in patients with cystic fibrosis (CF) infected with Pseudomonas aeruginosa (PA) or Burkholderia cepacia (BC)","volume":"36","author":"Blumer","year":"2003","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1378\/chest.128.4.2336","article-title":"The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis","volume":"128","author":"Blumer","year":"2005","journal-title":"Chest"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0016|cit16","first-page":"R(c)17","article-title":"A comparative trial of aztreonam and tobramycin plus azlocillin","volume":"74","author":"Bosso","year":"1988","journal-title":"Excerpta Medica, Asia Pacific Congress Series"},{"issue":"3","key":"10.1002\/14651858.CD009730.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00006454-198803000-00008","article-title":"Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis","volume":"7","author":"Bosso","year":"1988","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"4A","key":"10.1002\/14651858.CD009730.pub3-BIB0018|cit18","first-page":"180","article-title":"Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis","volume":"82","author":"Bosso","year":"1987","journal-title":"American Journal of Medicine"},{"issue":"Suppl 5a","key":"10.1002\/14651858.CD009730.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"123S","DOI":"10.1016\/0002-9343(89)90040-5","article-title":"Use of ciprofloxacin in cystic fibrosis patients","volume":"87","author":"Bosso","year":"1989","journal-title":"American Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/thx.40.5.358","article-title":"Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms","volume":"40","author":"British Thoracic Society Research Committee","year":"1985","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0021|cit21","unstructured":"Stack BH Geddes DM Williams KJ Dinwiddie R Selkon JB Godfrey RC Ceftazidime compared with a combination of gentamicin and carbenicillin in cystic fibrosis patients with persistent pulmonary pseudomonas infection and an acute exacerbation of respiratory symptoms 9th International Cystic Fibrosis Congress; 1984 Jun 9-15; Brighton, UK PI37b"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009730.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S705","DOI":"10.1093\/clinids\/6.Supplement_3.S705","article-title":"Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis","volume":"6","author":"Caplan","year":"1984","journal-title":"Reviews of Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD009730.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006454-199701000-00031","article-title":"Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime\/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group","volume":"16","author":"Church","year":"1997","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"1","key":"10.1002\/14651858.CD009730.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1651-2227.1985.tb10929.x","article-title":"Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin","volume":"74","author":"Conway","year":"1985","journal-title":"Acta Paediatrica Scandinavica"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0025|cit25","unstructured":"Conway SP Miller MG Ramsden CH Littlewood JM Comparison of netilmicin-plus ticarcillin and tobramycin plus ticarcillin in exacerbations of pseudomonas chest infection in cystic fibrosis 12th Annual Meeting European Working Group for Cystic Fibrosis; 1983 October; Athens, Greece"},{"issue":"11","key":"10.1002\/14651858.CD009730.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/thx.52.11.987","article-title":"Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis","volume":"52","author":"Conway","year":"1997","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0027|cit27","unstructured":"Conway SP Pond MN Watson AJ Robey E Goldman MH A safety profile of intravenous colomycin in adult CF care 20th European Cystic Fibrosis Conference; 1995 Jun 18-21; Brussels, Belgium"},{"issue":"Suppl 13","key":"10.1002\/14651858.CD009730.pub3-BIB0028|cit28","first-page":"296","article-title":"Colistin alone or in combination with a second antibiotic is effective in the treatment of respiratory exacerbations in cystic fibrosis","volume":"22","author":"Conway","year":"1996","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0029|cit29","first-page":"A242","article-title":"Comparison of intravenous and inhalation antibiotic therapy in acute pulmonary deterioration in cystic fibrosis","volume":"131","author":"Cooper","year":"1985","journal-title":"American Review of Respiratory Disease"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0030|cit30","unstructured":"Costantini D Padoan R Brienza A Lodi G Assael BM Giunta A Clinical evaluation of carbenicillin and sisomicin alone or in combination in CF patients with pulmonary exacerbations 11th European Cystic Fibrosis Conference; 1982; Brussels, Belgium"},{"issue":"3","key":"10.1002\/14651858.CD009730.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ppul.1950070310","article-title":"Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication","volume":"7","author":"De Boeck","year":"1989","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl","key":"10.1002\/14651858.CD009730.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0300-2977(99)90113-4","article-title":"Meropenem versus ceftazidime plus tobramycin for pulmonary disease in CF patients","volume":"54","author":"De Boeck","year":"1999","journal-title":"Netherlands Journal of Medicine"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0033|cit33","unstructured":"Elborn S Colville A Cordon S Hiller EJ Shale D A comparison of intravenous ceftazidime and aztreonam in the treatment of respiratory exacerbations in cystic fibrosis 11th International Cystic Fibrosis Congress; 1992; Dublin, Ireland"},{"issue":"2","key":"10.1002\/14651858.CD009730.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/00006454-198503000-00012","article-title":"Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis","volume":"4","author":"Gold","year":"1985","journal-title":"Pediatric Infectious Disease"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD009730.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-3476(87)80217-2","article-title":"Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis","volume":"111","author":"Gold","year":"1987","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0036|cit36","first-page":"38","article-title":"Mild to moderate chest exacerbations: do antibiotics help?","volume":"3","author":"Gold","year":"1987","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0037|cit37","first-page":"126","article-title":"Ciprofloxacin compared with intravenous azlocillin and gentamicin in the treatment of pseudomonas aeruginosa infection in cystic fibrosis (CF)","volume":"3","author":"Hodson","year":"1987","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0038|cit38","unstructured":"Hodson ME Roberts CM Butland RJ Batten JC Ciprofloxacin compared with intravenous azlocillin and gentamicin in the treatment of pseudomonas infection in cystic fibrosis (CF) 14th Annual Meeting of the European Working Group for Cystic Fibrosis; 1986 Sep 1-2; Budapest, Hungary 20"},{"issue":"8527","key":"10.1002\/14651858.CD009730.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(87)90062-6","article-title":"Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis","volume":"1","author":"Hodson","year":"1987","journal-title":"Lancet"},{"issue":"Suppl B","key":"10.1002\/14651858.CD009730.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jac\/11.suppl_B.205","article-title":"Comparative efficacy and tolerance study of azlocillin and carbenicillin in patients with cystic fibrosis: a double blind study","volume":"11","author":"Huang","year":"1983","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD009730.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0022-3476(81)80486-6","article-title":"A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis","volume":"99","author":"Hyatt","year":"1981","journal-title":"Journal of Pediatrics"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009730.pub3-BIB0042|cit42","first-page":"120","article-title":"Efficacy of aerosolized antibiotics combined with intravenous treatment of cystic fibrosis pulmonary exacerbation","volume":"5","author":"Knowles","year":"1988","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ppul.1950010506","article-title":"The role of piperacillin therapy in pulmonary exacerbations of cystic fibrosis: a controlled study","volume":"1","author":"Macfarlane","year":"1985","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 25","key":"10.1002\/14651858.CD009730.pub3-BIB0044|cit44","first-page":"162S","article-title":"Once daily tobramycin monotherapy versus conventional antibiotic therapy for the treatment of pseudomonal pulmonary exacerbations in cystic fibrosis patients","volume":"10","author":"Master","year":"1997","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ppul.1060","article-title":"Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study","volume":"31","author":"Master","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ppul.1950040403","article-title":"Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis","volume":"4","author":"McCarty","year":"1988","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl B","key":"10.1002\/14651858.CD009730.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/jac\/11.suppl_B.195","article-title":"Randomized, double-blind evaluation of azlocillin for the treatment of pulmonary exacerbations of cystic fibrosis","volume":"11","author":"McLaughlin","year":"1983","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"3","key":"10.1002\/14651858.CD009730.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/infdis\/147.3.559","article-title":"Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo","volume":"147","author":"McLaughlin","year":"1983","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0049|cit49","unstructured":"IV colistin for pulmonary exacerbations: improving safety and efficacy clinicaltrials.gov\/show\/nct02918409"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0050|cit50","unstructured":"Padoan R Cambisano W Costantini D Crossignani R Giunta A Pseudomonas pulmonary infections in cystic fibrosis: ceftazidime vs ceftazidime plus sisomicin vs piperacillin plus sisomicin 9th International Cystic Fibrosis Congress; 1984 Jun 9-15; Brighton, UK"},{"issue":"7","key":"10.1002\/14651858.CD009730.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/00006454-198707000-00006","article-title":"Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis","volume":"6","author":"Padoan","year":"1987","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Penketh AR Hodson ME Batten JC Ticarcillin compared with carbenicillin in the treatment of exacerbations of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis 11th European Cystic Fibrosis Conference; 1982; Brussels, Belgium","DOI":"10.1016\/0007-0971(83)90025-6"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Penketh AR Hodson ME Batten JC Ticarcillin compared with carbenicillin in the treatment of exacerbations of bronchopulmonary infection in cystic fibrosis [abstract] Research Conference 1982 Poster Abstract 3","DOI":"10.1016\/0007-0971(83)90025-6"},{"issue":"2","key":"10.1002\/14651858.CD009730.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0007-0971(83)90025-6","article-title":"Ticarcillin compared with carbenicillin in the treatment of exacerbations of bronchopulmonary infection in cystic fibrosis","volume":"77","author":"Penketh","year":"1983","journal-title":"British Journal of Diseases of the Chest"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0055|cit55","unstructured":"Penketh AR Hodson ME Gaya H Batten JC Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis [abstract] Research Conference 1982 1"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/thx.39.4.299","article-title":"Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis","volume":"39","author":"Penketh","year":"1984","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0057|cit57","unstructured":"Comparison between intravenous aminoglycosides versus nebulize aminoglycosides in cystic fibrosis patients trialsearch.who.int\/Trial2.aspx?TrialID=IRCT20120415009475N10"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"1130374","DOI":"10.3389\/fphar.2023.1130374","article-title":"Evaluating the efficacy of inhaled amikacin as an adjunct to intravenous combination therapy (ceftazidime and amikacin) in pediatric cystic fibrosis pulmonary exacerbation","volume":"14","author":"Rakhshan","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0059|cit59","first-page":"97","article-title":"Reduction of sputum Ps. Aeruginosa density by antibiotics improves lung function in CF more than bronchodilators and chest physiotherapy alone","volume":"Suppl 2","author":"Regelmann","year":"1988","journal-title":"Pediatric Pulmonology"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD009730.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1164\/ajrccm\/141.4_Pt_1.914","article-title":"Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone","volume":"141","author":"Regelmann","year":"1990","journal-title":"American Review of Respiratory Disease"},{"issue":"6","key":"10.1002\/14651858.CD009730.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/00006454-199706000-00007","article-title":"Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group","volume":"16","author":"Richard","year":"1997","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"2","key":"10.1002\/14651858.CD009730.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/00365549209052615","article-title":"A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis","volume":"24","author":"Salh","year":"1992","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD009730.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1651-2227.1986.tb10169.x","article-title":"Antimicrobial therapy of Pseudomonas pulmonary exacerbations in cystic fibrosis. A prospective evaluation of netilmicin plus azlocillin versus netilmicin plus ticarcillin","volume":"75","author":"Schaad","year":"1986","journal-title":"Acta Paediatrica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0022-3476(87)80130-0","article-title":"Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis","volume":"111","author":"Schaad","year":"1987","journal-title":"Journal of Pediatrics"},{"issue":"10","key":"10.1002\/14651858.CD009730.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/BF01963771","article-title":"Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin","volume":"8","author":"Schaad","year":"1989","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009730.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S1569-1993(10)60215-9","article-title":"Efficiency of the inhalational tobramycin therapy in complex antibacterial therapy of lung exacerbation in cystic fibrosis children with chronic pseudomonas aeruginosa infection","volume":"9","author":"Semykin","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0022-3476(99)70197-6","article-title":"Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis","volume":"134","author":"Smith","year":"1999","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD009730.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00006454-198305000-00007","article-title":"Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis","volume":"2","author":"Stephens","year":"1983","journal-title":"Pediatric Infectious Disease"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009730.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1569-1993(18)30390-4","article-title":"Design, enrollment, and feasibility of the STOP-2 randomised study of intravenous antibiotic treatment duration in cystic fibrosis pulmonary exacerbations","volume":"17","author":"Flume","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0070|cit70","doi-asserted-by":"crossref","unstructured":"Gold LS Hansen RN Heltshe SL Flume PA Goss CH West NE Characteristics associated with cystic fibrosis-related pulmonary exacerbation treatment location Journal of Cystic Fibrosis 2024 23 2 278 81","DOI":"10.1016\/j.jcf.2023.10.004"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jcf.2022.03.001","article-title":"Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations","volume":"21","author":"Gold","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"11","key":"10.1002\/14651858.CD009730.pub3-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","article-title":"A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment","volume":"204","author":"Goss","year":"2021","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 47","key":"10.1002\/14651858.CD009730.pub3-BIB0073|cit73","first-page":"388","article-title":"Design, enrollment, and feasibility of the STOP-2 randomised study of iv antibiotic duration in CF pulmonary exacerbations","volume":"52","author":"Heltshe","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cct.2017.11.012","article-title":"Study design considerations for the standardized treatment of pulmonary exacerbations 2 (STOP2): a trial to compare intravenous antibiotic treatment durations in CF","volume":"64","author":"Heltshe","year":"2018","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/S1569-1993(23)00471-X","article-title":"Effect of acute systemic corticosteroids on clinical outcomes in cystic fibrosis pulmonary exacerbations","volume":"22","author":"McElvaney","year":"2023","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1513\/AnnalsATS.202308-673OC","article-title":"Adjunctive systemic corticosteroids for pulmonary exacerbations of cystic fibrosis","volume":"21","author":"McElvaney","year":"2024","journal-title":"Annals of the American Thoracic Society"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0077|cit77","doi-asserted-by":"crossref","unstructured":"McElvaney OJ Heltshe SL Odem-Davis K West NE Sanders DB Fogarty B Impact of lumacaftor\/ivacaftor and tezacaftor\/ivacaftor on treatment response in pulmonary exacerbations of F508del\/F508del cystic fibrosis Journal of Cystic Fibrosis 2023 22 5 875 9 10.1016\/j.jcf.2023.06.012","DOI":"10.1016\/j.jcf.2023.06.012"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S1569-1993(22)00695-6","article-title":"Role of hyperglycemia in cystic fibrosis pulmonary exacerbations","volume":"21","author":"Merjaneh","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jcf.2023.06.011","article-title":"Role of hyperglycemia in cystic fibrosis pulmonary exacerbations","volume":"22","author":"Merjaneh","year":"2023","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/S1569-1993(22)00819-0","article-title":"Sex-based differences in cystic fibrosis pulmonary exacerbations: subanalysis of the standardized treatment of pulmonary exacerbations-2 cohort","volume":"21","author":"Montemayor","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD009730.pub3-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"A5105","DOI":"10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A5105","article-title":"Evaluation of sex differences in clinical outcomes in people with cystic fibrosis requiring intravenous antimicrobial therapies for a pulmonary exacerbation: sub-analysis of the STOP2 cohort","volume":"205","author":"Montemayor","year":"2022","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0082|cit82","unstructured":"Standardized treatment of pulmonary exacerbations II clinicaltrials.gov\/show\/nct02781610"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/S1569-1993(21)01578-2","article-title":"Site of intravenous antimicrobial treatment of pulmonary exacerbations in the STOP2 study: home versus hospital","volume":"20","author":"Sanders","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S2","key":"10.1002\/14651858.CD009730.pub3-BIB0084|cit84","first-page":"324","article-title":"Update on the STOP-2 randomized study of IV antibiotic duration in CF pulmonary exacerbations","volume":"53","author":"Sanders","year":"2018","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jcf.2021.11.009","article-title":"Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation","volume":"21","author":"Sanders","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"S287","DOI":"10.1016\/S1569-1993(22)01200-0","article-title":"Prevalence and clinical impact of respiratory viral infections in the Standardized Treatment of Pulmonary Exacerbations 2 Study","volume":"21","author":"Thornton","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1513\/AnnalsATS.202306-576OC","article-title":"Prevalence and clinical impact of respiratory viral infections from the STOP2 study of cystic fibrosis pulmonary exacerbations","volume":"21","author":"Thornton","year":"2024","journal-title":"Annals of the American Thoracic Society"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/S1569-1993(21)00968-1","article-title":"A randomised clinical trial of antimicrobial duration for treatment of cystic fibrosis pulmonary exacerbations (STOP2)","volume":"20","author":"West","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 47","key":"10.1002\/14651858.CD009730.pub3-BIB0089|cit89","first-page":"124","article-title":"Treatment of pulmonary exacerbations","volume":"52","author":"West","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/S1569-1993(21)01582-4","article-title":"C-reactive protein (CRP) as a biomarker of exacerbation presentation and treatment response","volume":"20","author":"vanDevanter","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jcf.2022.04.006","article-title":"Antipseudomonal treatment decisions during CF exacerbation management","volume":"21","author":"vanDevanter","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009730.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1569-1993(18)30390-4","article-title":"Design, enrollment, and feasibility of the STOP-2 randomised study of intravenous antibiotic treatment duration in cystic fibrosis pulmonary exacerbations","volume":"17","author":"Flume","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0093|cit93","doi-asserted-by":"crossref","unstructured":"Gold LS Hansen RN Heltshe SL Flume PA Goss CH West NE Characteristics associated with cystic fibrosis-related pulmonary exacerbation treatment location Journal of Cystic Fibrosis 2024 23 2 278 81","DOI":"10.1016\/j.jcf.2023.10.004"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jcf.2022.03.001","article-title":"Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations","volume":"21","author":"Gold","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"11","key":"10.1002\/14651858.CD009730.pub3-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","article-title":"A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment","volume":"204","author":"Goss","year":"2021","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 47","key":"10.1002\/14651858.CD009730.pub3-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/ppul.23840","article-title":"Design, enrollment, and feasibility of the STOP-2 randomized study of IV antibiotic duration in CF pulmonary exacerbations","volume":"52","author":"Heltshe","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cct.2017.11.012","article-title":"Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): a trial to compare intravenous antibiotic treatment durations in CF","volume":"64","author":"Heltshe","year":"2018","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/S1569-1993(23)00471-X","article-title":"Effect of acute systemic corticosteroids on clinical outcomes in cystic fibrosis pulmonary exacerbations","volume":"22","author":"McElvaney","year":"2023","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1513\/AnnalsATS.202308-673OC","article-title":"Adjunctive systemic corticosteroids for pulmonary exacerbations of cystic fibrosis","volume":"21","author":"McElvaney","year":"2024","journal-title":"Annals of the American Thoracic Society"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jcf.2023.06.012","article-title":"Impact of lumacaftor\/ivacaftor and tezacaftor\/ivacaftor on treatment response in pulmonary exacerbations of F508del\/F508del cystic fibrosis","volume":"22","author":"McElvaney","year":"2023","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S1569-1993(22)00695-6","article-title":"Role of hyperglycemia in cystic fibrosis pulmonary exacerbations","volume":"21","author":"Merjaneh","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jcf.2023.06.011","article-title":"Role of hyperglycemia in cystic fibrosis pulmonary exacerbations","volume":"22","author":"Merjaneh","year":"2023","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/S1569-1993(22)00819-0","article-title":"Sex-based differences in cystic fibrosis pulmonary exacerbations: subanalysis of the Standardized Treatment of Pulmonary Exacerbations-2 cohort","volume":"21","author":"Montemayor","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD009730.pub3-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"A5105","DOI":"10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A5105","article-title":"Evaluation of sex differences in clinical outcomes in people with cystic fibrosis requiring intravenous antimicrobial therapies for a pulmonary exacerbation: sub-analysis of the STOP2 cohort","volume":"205","author":"Montemayor","year":"2022","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0105|cit105","unstructured":"Standardized treatment of pulmonary exacerbations II clinicaltrials.gov\/show\/nct02781610"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/S1569-1993(21)01578-2","article-title":"Site of intravenous antimicrobial treatment of pulmonary exacerbations in the STOP2 study: home versus hospital","volume":"20","author":"Sanders","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S2","key":"10.1002\/14651858.CD009730.pub3-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/ppul.24152","article-title":"Update on the STOP-2 randomized study of IV antibiotic duration in CF pulmonary exacerbations","volume":"53","author":"Sanders","year":"2018","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jcf.2021.11.009","article-title":"Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation","volume":"21","author":"Sanders","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"S287","DOI":"10.1016\/S1569-1993(22)01200-0","article-title":"Prevalence and clinical impact of respiratory viral infections in the Standardized Treatment of Pulmonary Exacerbations 2 Study","volume":"21","author":"Thornton","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1513\/AnnalsATS.202306-576OC","article-title":"Prevalence and clinical impact of respiratory viral infections from the STOP2 study of cystic fibrosis pulmonary exacerbations","volume":"21","author":"Thornton","year":"2024","journal-title":"Annals of the American Thoracic Society"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/S1569-1993(21)00968-1","article-title":"A randomised clinical trial of antimicrobial duration for treatment of cystic fibrosis pulmonary exacerbations (STOP2)","volume":"20","author":"West","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 47","key":"10.1002\/14651858.CD009730.pub3-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/ppul.23839","article-title":"Treatment of pulmonary exacerbations","volume":"52","author":"West","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/S1569-1993(21)01582-4","article-title":"C-reactive protein (CRP) as a biomarker of exacerbation presentation and treatment response","volume":"20","author":"vanDevanter","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jcf.2022.04.006","article-title":"Antipseudomonal treatment decisions during CF exacerbation management","volume":"21","author":"vanDevanter","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0115|cit115","first-page":"R(c)19","article-title":"Comparison of the efficacy and safety of oral ciprofloxacin with that of i.v. tobramycin plus azlocillin and\/or tobramycin plus ticarcillin in patients with cystic fibrosis","volume":"74","author":"Wang","year":"1988","journal-title":"Excerpta Medica, Asia Pacific Congress Series"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0116|cit116","first-page":"R(c)13","article-title":"A double-blind comparison of ceftazidime with tobramycin and ticarcillin in the treatment of exacerbations of pseudomonas chest infection in children with cystic fibrosis","volume":"74","author":"Wesley","year":"1988","journal-title":"Excerpta Medica, Asia Pacific Congress Series"},{"issue":"12","key":"10.1002\/14651858.CD009730.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1001\/archpedi.1980.02130240018007","article-title":"Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy","volume":"134","author":"Wientzen","year":"1980","journal-title":"American Journal of Diseases of Children"},{"issue":"1","key":"10.1002\/14651858.CD009730.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jcf.2010.09.003","article-title":"Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis","volume":"10","author":"Adeboyeku","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 27","key":"10.1002\/14651858.CD009730.pub3-BIB0119|cit119","first-page":"249","article-title":"A randomised cross over trial of TOBI\u00ae vs IV tobramycin in acute pulmonary exacerbations in CF","volume":"38","author":"Al-Aloul","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl II","key":"10.1002\/14651858.CD009730.pub3-BIB0120|cit120","first-page":"ii79","article-title":"Tobramycin nebuliser solution (TOBI): a renal sparing alternative to intravenous (IV) tobramycin in acute pulmonary exacerbations in CF","volume":"59","author":"Al-Aloul","year":"2004","journal-title":"Thorax"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009730.pub3-BIB0121|cit121","first-page":"ii92","article-title":"Tobramycin nebuliser solution in the treatment of cystic fibrosis pulmonary exacerbations: effect on sputum pseudomonas aeruginosa density","volume":"2","author":"Al-Aloul","year":"2005","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/jamp.2013.1055","article-title":"Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations","volume":"27","author":"Al-Aloul","year":"2014","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/ckj\/sfz005","article-title":"The renoprotective effect of concomitant fosfomycin in the treatment of pulmonary exacerbations in cystic fibrosis","volume":"12","author":"Al-Aloul","year":"2019","journal-title":"Clinical Kidney Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009730.pub3-BIB0124|cit124","first-page":"iii85","article-title":"Efficacy of once daily tobramycin for acute pulmonary exacerbations of cystic fibrosis (CF) \u2013 a microbiological perspective","volume":"56","author":"Al-Ansari","year":"2001","journal-title":"Thorax"},{"issue":"1","key":"10.1002\/14651858.CD009730.pub3-BIB0125|cit125","first-page":"34","article-title":"Evaluation of once daily tobramycin versus the traditional three times daily for the treatment of acute pulmonary exacerbations in adult cystic fibrosis patients","volume":"15","author":"Al-Ansari","year":"2006","journal-title":"Qatar Medical Journal"},{"issue":"Suppl 31","key":"10.1002\/14651858.CD009730.pub3-BIB0126|cit126","first-page":"123s","article-title":"Home intravenous therapy in adult cystic fibrosis patients. The impact on lung function and quality of life","volume":"16","author":"Amelina","year":"2000","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jac\/dkf168","article-title":"Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis","volume":"50","author":"Aminimanizani","year":"2002","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"Suppl 20","key":"10.1002\/14651858.CD009730.pub3-BIB0128|cit128","first-page":"284","article-title":"Pharmacokinetics of once-daily tobramycin in adult cystic fibrosis patients","volume":"30","author":"Tsang","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 33","key":"10.1002\/14651858.CD009730.pub3-BIB0129|cit129","first-page":"370","article-title":"Safety, pharmacokinetics and preliminary evaluation of the antiinflammatory effect of doxycycline in CF","volume":"45","author":"Beringer","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD009730.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1128\/AAC.05710-11","article-title":"Pharmacokinetics of doxycycline in adults with cystic fibrosis","volume":"56","author":"Beringer","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/jac\/dkl328","article-title":"Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?","volume":"58","author":"Burkhardt","year":"2006","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"Suppl 27","key":"10.1002\/14651858.CD009730.pub3-BIB0132|cit132","first-page":"288","article-title":"Once-daily versus thrice-daily tobramycin in adult cystic fibrosis patients chronically infected with pseudomonas aeruginosa","volume":"38","author":"Lehmann","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD009730.pub3-BIB0133|cit133","first-page":"449","article-title":"Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis","volume":"46","author":"Canis","year":"1998","journal-title":"Pathologie-Biologie (Paris)"},{"issue":"Suppl 13","key":"10.1002\/14651858.CD009730.pub3-BIB0134|cit134","first-page":"293","article-title":"Efficacy, tolerance and pharmacokinetics of once-daily (OD) versus thrice-daily (TD) tobramycin (TBM) for pseudomonas aeruginosa (PA) pulmonary exacerbations","volume":"22","author":"Vic","year":"1996","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD009730.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/adc.78.6.536","article-title":"Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis","volume":"78","author":"Vic","year":"1998","journal-title":"Archives of Disease in Childhood"},{"issue":"11","key":"10.1002\/14651858.CD009730.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1128\/AAC.36.11.2512","article-title":"Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients","volume":"36","author":"Christensson","year":"1992","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0137|cit137","first-page":"84","article-title":"Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection","volume":"60","author":"Strandvik","year":"1989","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"Suppl","key":"10.1002\/14651858.CD009730.pub3-BIB0138|cit138","first-page":"S256","article-title":"Ceftazidime 3G BD is as effective as ceftazidime 2G TDS in the treatment of respiratory exacerbations in cystic fibrosis","volume":"32","author":"Conway","year":"1996","journal-title":"Israel Journal of Medical Sciences"},{"issue":"6","key":"10.1002\/14651858.CD009730.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1128\/AAC.31.6.915","article-title":"Pharmacokinetics of ciprofloxacin in cystic fibrosis","volume":"31","author":"Davis","year":"1987","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD009730.pub3-BIB0140|cit140","first-page":"245","article-title":"A randomized trial of home intravenous antibiotic therapy (HIVAT) in cystic fibrosis (CF): short-term safety and efficacy","volume":"9","author":"Davis","year":"1990","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD009730.pub3-BIB0141|cit141","first-page":"281","article-title":"A randomized trial of home intravenous antibiotic therapy (HIVAT) in cystic fibrosis (CF): short-term psychological effects","volume":"9","author":"Davis","year":"1990","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0142|cit142","unstructured":"Day AJ Williams J McKeown C Bruton A Weller PH Evaluation of inhaled colomycin in children with cystic fibrosis Excerpta Medica, Asia Pacific Congress Series 1988 74 R(c)3"},{"issue":"3","key":"10.1002\/14651858.CD009730.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/jac\/41.3.407","article-title":"Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime","volume":"41","author":"De Boeck","year":"1998","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD009730.pub3-BIB0144|cit144","first-page":"99","article-title":"The effect of frequent exposure to gentamicin on distortion product OAEs in patients with cystic fibrosis","volume":"30","author":"Degg","year":"1996","journal-title":"British Journal of Audiology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0145|cit145","unstructured":"Dinwiddie R Hindmarsh P Lock P Azlocillin compared to gentamicin in the treatment of pseudomonas infection in cystic fibrosis 11th European Cystic Fibrosis Conference; 1982; Brussels, Belgium"},{"issue":"Suppl A","key":"10.1002\/14651858.CD009730.pub3-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/jac\/12.suppl_A.325","article-title":"Experience with ceftazidime in cystic fibrosis","volume":"12","author":"Dodge","year":"1983","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD009730.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0022-3476(87)80337-2","article-title":"Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease","volume":"111","author":"Donati","year":"1987","journal-title":"Journal of Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0148|cit148","first-page":"A248","article-title":"Impact of antibiotic therapy on neutrophil elastase release in cystic fibrosis patients","volume":"151","author":"D\u00f6ring","year":"1995","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD009730.pub3-BIB0149|cit149","first-page":"A4","article-title":"A comparison of the clinical outcome of symptomatic and elective regular intravenous antibiotics in the treatment of cystic fibrosis","volume":"52","author":"Elborn","year":"1997","journal-title":"Thorax"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD009730.pub3-BIB0150|cit150","first-page":"434","article-title":"Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs","volume":"30","author":"Elborn","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/thorax.55.5.355","article-title":"Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs","volume":"55","author":"Elborn","year":"2000","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0152|cit152","unstructured":"Elborn JS Prescott RJ Stack BH The British Thoracic Society study of elective versus symptomatic treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis: 5 year results 13th International Cystic Fibrosis Congress; 2000 Jun 4-8; Stockholm, Sweden"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0153|cit153","unstructured":"Once daily deep inhalation of tobramycin with smart nebulizer more effective to treat small airways disease in cystic fibrosis? trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2014-001401-41-NL 2014"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0154|cit154","unstructured":"Evaluation of the efficacy of antibiotic treatments associated with Nebcine\u00ae as intravenous injection only and\/or monitoring of aerosols of Tobi\u00ae in order to optimize the therapeutic management of exacerbations in patients with cystic fibrosis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2014-003882-10-FR 2015"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0155|cit155","unstructured":"Evaluation of short antibiotic combination courses followed by aerosols in cystic fibrosis (TOBRAMUC) clinicaltrials.gov\/show\/NCT03066453"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009730.pub3-BIB0156|cit156","first-page":"S22","article-title":"Cross-over study of TOBI\u00ae vs. intravenous tobramycin in combination treatment of pulmonary exacerbations in cystic fibrosis patients","volume":"2","author":"Geborek","year":"2003","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/jac\/37.5.1040","article-title":"Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients [letter]","volume":"37","author":"Guglielmo","year":"1996","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009730.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S1569-1993(17)30338-7","article-title":"Combined dry powder tobramycin and nebulized colistin versus colistin inhalation in CF patients \u2013 a randomised, open label phase III clinical study","volume":"16","author":"Herrmann","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"issue":"18","key":"10.1002\/14651858.CD009730.pub3-BIB0159|cit159","first-page":"1614","article-title":"Intravenous administration of antibiotics at home in patients with cystic fibrosis improves quality of life","volume":"85","author":"Hjelte","year":"1988","journal-title":"Lakartidningen"},{"issue":"9","key":"10.1002\/14651858.CD009730.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1128\/AAC.00174-09","article-title":"Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis","volume":"53","author":"Hubert","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Suppl 25","key":"10.1002\/14651858.CD009730.pub3-BIB0161|cit161","first-page":"294","article-title":"Continuous infusion versus intermittent administration of ceftazidime in cystic fibrosis patients","volume":"36","author":"Hubert","year":"2003","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0162|cit162","unstructured":"Continuous versus short infusions of ceftazidime in cystic fibrosis clinicaltrials.gov\/show\/NCT00333385"},{"issue":"Suppl 14","key":"10.1002\/14651858.CD009730.pub3-BIB0163|cit163","first-page":"292","article-title":"Ceftazidime bid vs tid in the treatment of bacterial respiratory exacerbations in Russian cystic fibrosis","volume":"25","author":"Ivanov","year":"1997","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD009730.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0022-3476(85)80258-4","article-title":"Ticarcillin\/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis","volume":"106","author":"Jacobs","year":"1985","journal-title":"Journal of Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0022-3476(85)80100-1","article-title":"Comparison of cefoperazone sodium vs methicillin, ticarcillin, and tobramycin in treatment of pulmonary exacerbations in patients with cystic fibrosis","volume":"106","author":"Jewett","year":"1985","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0166|cit166","unstructured":"Kapranov NI Belousov YB Kashyrskaya NY Smirnova EY Quinoline therapy in children with cystic fibrosis 20th European Cystic Fibrosis Conference; 1995 Jun 18-21; Brussels, Belgium"},{"issue":"7","key":"10.1002\/14651858.CD009730.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1128\/AAC.01797-10","article-title":"Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis","volume":"55","author":"Keel","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Suppl A","key":"10.1002\/14651858.CD009730.pub3-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/jac\/12.suppl_A.289","article-title":"Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response","volume":"12","author":"Kercsmar","year":"1983","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD009730.pub3-BIB0169|cit169","first-page":"31","article-title":"Ambulatory vs. inpatient intravenous antibiotic therapy in mucoviscidosis patients \u2013 a controlled study","volume":"53","author":"Klettke","year":"1999","journal-title":"Pneumologie (Stuttgart, Germany)"},{"issue":"Suppl 13","key":"10.1002\/14651858.CD009730.pub3-BIB0170|cit170","first-page":"340","article-title":"Can home therapy replace hospital intravenous antibiotic therapy in patients with cystic fibrosis in Germany?","volume":"22","author":"Klettke","year":"1996","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0171|cit171","first-page":"1047","article-title":"Home intravenous antibiotic therapy vs. hospital therapy \u2013 an alternative for patients with cystic fibrosis?","volume":"144","author":"Magdorf","year":"1996","journal-title":"Monatsschrift fur Kinderheilkunde"},{"issue":"10","key":"10.1002\/14651858.CD009730.pub3-BIB0172|cit172","first-page":"626","article-title":"Economic aspects in treatment of cystic fibrosis with chronic pulmonary pseudomonas infection. Ambulatory intravenous therapy in comparison with inpatient treatment","volume":"92","author":"Schulenburg","year":"1997","journal-title":"Medizinische Klinik"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0173|cit173","first-page":"609","article-title":"The treatment of exacerbations of pulmonary disease in cystic fibrosis: netilmicin compared with netilmicin and carbenicillin","volume":"25","author":"Krause","year":"1979","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"Suppl 22","key":"10.1002\/14651858.CD009730.pub3-BIB0174|cit174","first-page":"291","article-title":"Once daily dosage of intravenous tobramycin \u2013 increased risk for cochlea damage in children with cystic fibrosis (CF)?","volume":"32","author":"Junge","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0175|cit175","unstructured":"Kruger K Junge S Schonweiler R Ptok M Ballmann M Once daily dosage of intravenous tobramycin in patients with cystic fibrosis \u2013 increased risk for cochlea damage? 24th European Cystic Fibrosis Conference; 2001 Jun 6-9; Vienna, Austria"},{"issue":"2","key":"10.1002\/14651858.CD009730.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00003072-199202000-00002","article-title":"Aerosol scintigraphy in the assessment of therapy for cystic fibrosis","volume":"17","author":"Kuni","year":"1992","journal-title":"Clinical Nuclear Medicine"},{"issue":"8659","key":"10.1002\/14651858.CD009730.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(89)90561-8","article-title":"Continuous infusion of ceftazidime in cystic fibrosis [letter]","volume":"2","author":"Kuzemko","year":"1989","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD009730.pub3-BIB0178|cit178","first-page":"A307","article-title":"Does inhalation of preservatives from IV tobramycin preparations (TOB) cause airway inflammation?","volume":"169","author":"Labiris","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009730.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jcf.2007.07.001","article-title":"Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis","volume":"7","author":"Latzin","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD009730.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/jac\/10.3.227","article-title":"Comparative study of the antibacterial activity of amikacin and tobramycin during Pseudomonas pulmonary infection in patients with cystic fibrosis","volume":"10","author":"Levy","year":"1982","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/adc.55.8.604","article-title":"Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis","volume":"55","author":"Martin","year":"1980","journal-title":"Archives of Disease in Childhood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009730.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S1569-1993(13)60231-3","article-title":"Evaluation of a twice daily tobramycin regimen in adult cystic fibrosis patients","volume":"12","author":"McCabe","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0183|cit183","unstructured":"What duration of intravenous antibiotic therapy should be used in the treatment of infective exacerbations of cystic fibrosis in patients chronically colonised with Pseudomonas aeruginosa? \u2013 duration of antibiotics in infective exacerbations of cystic fibrosis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2009-014042-28-GB"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0184|cit184","unstructured":"Duration of antibiotics in infective exacerbations of cystic fibrosis clinicaltrials.gov\/show\/NCT01044719"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0185|cit185","unstructured":"Streamlined treatment of pulmonary exacerbations in pediatrics clinicaltrials.gov\/show\/NCT04608019"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1155\/2008\/202464","article-title":"A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients","volume":"15","author":"Nikolaizik","year":"2008","journal-title":"Canadian Respiratory Journal"},{"issue":"Suppl 49","key":"10.1002\/14651858.CD009730.pub3-BIB0187|cit187","first-page":"620s","article-title":"Comparison of tobramycin 80 mg (IV-preparation) and 300mg solution for inhalation in cystic fibrosis patients","volume":"26","author":"Nikolaizik","year":"2005","journal-title":"European Respiratory Journal"},{"issue":"Suppl","key":"10.1002\/14651858.CD009730.pub3-BIB0188|cit188","first-page":"S53","article-title":"Comparison of tobramycin 80mg (IV-preparation) and 300mg solution inhaled twice daily for chronic P. aeruginosa infection","volume":"4","author":"Nikolaizik","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0189|cit189","first-page":"R(c)12","article-title":"Ceftazidime once a day vs t.i.d. in pseudomonas lung infection in cystic fibrosis patients","volume":"74","author":"Padoan","year":"1988","journal-title":"Excerpta Medica, Asia Pacific Congress Series"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0190|cit190","unstructured":"Pharmacokinetics of tedizolid phosphate in cystic fibrosis clinicaltrials.gov\/show\/NCT02444234"},{"issue":"9","key":"10.1002\/14651858.CD009730.pub3-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"e00550","DOI":"10.1128\/AAC.00550-18","article-title":"Pharmacokinetics of tedizolid in plasma and sputum of adults with cystic fibrosis","volume":"62","author":"Park","year":"2018","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD009730.pub3-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"S293","DOI":"10.1093\/ofid\/ofx163.670","article-title":"Pharmacokinetics of tedizolid in adults with cystic fibrosis","volume":"4","author":"Wang","year":"2017","journal-title":"Open Forum Infectious Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009730.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S1569-1993(07)60126-X","article-title":"A prospective trial on the efficacy and tolerability of twice-daily dosing (TDD) versus once-daily dosing (ODD) amikacin in cystic fibrosis patients","volume":"6","author":"Postnikov","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0194|cit194","unstructured":"Powell SH Stern RC Thompson WL Safety of once daily therapy with high-dose tobramycin 20th Annual Meeting Cystic Fibrosis Club Abstracts; 1979 May 1; Atlanta, Georgia"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/infdis\/147.5.918","article-title":"Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin","volume":"147","author":"Powell","year":"1983","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0196|cit196","unstructured":"Circadian rhythm in tobramycin elimination in cystic fibrosis clinicaltrials.gov\/show\/NCT01207245"},{"issue":"Suppl 36","key":"10.1002\/14651858.CD009730.pub3-BIB0197|cit197","first-page":"299","article-title":"Are morning doses of intravenous tobramycin less nephrotoxic than evening? Evidence from urinary biomarkers in the critic study","volume":"48","author":"Prayle","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jcf.2015.07.012","article-title":"The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: a randomised comparison","volume":"15","author":"Prayle","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD009730.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2710.2000.00319.x","article-title":"Pharmaceutical intervention in the care of cystic fibrosis patients","volume":"25","author":"Ramstrom","year":"2000","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD009730.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ppul.1950030212","article-title":"Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis","volume":"3","author":"Reed","year":"1987","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1128\/AAC.31.5.698","article-title":"Randomized double-blind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis","volume":"31","author":"Reed","year":"1987","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s15010-009-8117-4","article-title":"Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients","volume":"37","author":"Riethmueller","year":"2009","journal-title":"Infection"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0203|cit203","unstructured":"Riethmueller J Busch A Franke P Ziebach R von Butler R Stern M Pharmacodynamic variation of intravenous antibiotic treatment with ceftazidime and tobramycin in CF-patients is equally effective 13th International Cystic Fibrosis Congress; 2000 Jun 4-8; Stockholm, Sweden"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0204|cit204","unstructured":"Riethmueller J Franke P Schroeter TW Claass A Busch A Ziebach R Optimised intravenous antibiotic treatment with ceftazidime (thrice daily vs continuous) and tobramycin (thrice vs once daily) in CF patients 24th European Cystic Fibrosis Conference; 2001 Jun 6-9; Vienna, Austria"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s15010-009-8116-5","article-title":"Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis","volume":"37","author":"Riethmueller","year":"2009","journal-title":"Infection"},{"issue":"Suppl 24","key":"10.1002\/14651858.CD009730.pub3-BIB0206|cit206","first-page":"289","article-title":"Acute-phase nephrotoxicity of tobramycin in CF patients: a prospective randomized trial of once-versus thrice-daily dosing","volume":"34","author":"Schroeter","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0207|cit207","unstructured":"Schroeter TW Eggert P Riethmueller J Stern M Claass A A prospective randomized trial on the nephrotoxicity of thrice-daily versus once-daily tobramycin in cystic fibrosis patients 24th European Cystic Fibrosis Conference; 2001 Jun 6-9; Vienna, Austria"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1365-2125.1993.tb00380.x","article-title":"An in vivo assessment of the tobramycin\/ticarcillin interaction in cystic fibrosis patients","volume":"36","author":"Roberts","year":"1993","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD009730.pub3-BIB0209|cit209","first-page":"152","article-title":"Measurement of serum tobramycin in the presence of ticarcillin or piperacillin","volume":"22","author":"Roberts","year":"1992","journal-title":"Australian Journal of Hospital Pharmacy"},{"issue":"Suppl 4A","key":"10.1002\/14651858.CD009730.pub3-BIB0210|cit210","first-page":"185","article-title":"Ciprofloxacin: comparative data in cystic fibrosis","volume":"82","author":"Rubio","year":"1987","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009730.pub3-BIB0211|cit211","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13063-023-07076-8","article-title":"BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis","volume":"24","author":"Schultz","year":"2023","journal-title":"Trials"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0212|cit212","unstructured":"Shatunov SM Comparative efficacy of different methods of ceftazidime administration in children with cystic fibrosis 11th European Respiratory Society Annual Congress; 2001 Sep 22-26; Berlin"},{"issue":"7","key":"10.1002\/14651858.CD009730.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/AAC.00995-05","article-title":"Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients","volume":"50","author":"Mulheran","year":"2006","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009730.pub3-BIB0214|cit214","first-page":"iii84","article-title":"Once daily tobramycin achieves cidal levels against Pseudomonas aeruginosa in patients with cystic fibrosis","volume":"56","author":"Smyth","year":"2001","journal-title":"Thorax"},{"issue":"Suppl 25","key":"10.1002\/14651858.CD009730.pub3-BIB0215|cit215","first-page":"292","article-title":"A randomised controlled trial of once vs three times daily tobramycin for pulmonary exacerbations of cystic fibrosis (the TOPIC study)","volume":"36","author":"Smyth","year":"2003","journal-title":"Pediatric Pulmonology"},{"issue":"9459","key":"10.1002\/14651858.CD009730.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis \u2013 the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009730.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(07)60054-X","article-title":"Population pharmacokinetics (PK) of tobramycin administered thrice daily (TD) and once daily (OD) in children and adults with CF","volume":"6","author":"Touw","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcf.2006.12.007","article-title":"Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis","volume":"6","author":"Touw","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"issue":"9459","key":"10.1002\/14651858.CD009730.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(05)70769-8","article-title":"Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs? [Comment]","volume":"365","author":"Vandenbussche","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0220|cit220","unstructured":"Continuous infusion piperacillin-tazobactam for the treatment of cystic fibrosis (PIPE-CF) clinicaltrials.gov\/show\/NCT01694069"},{"issue":"Suppl 36","key":"10.1002\/14651858.CD009730.pub3-BIB0221|cit221","first-page":"326","article-title":"A randomized pilot study of continuous versus intermittent infusion piperacillin-tazobactam for the treatment of pulmonary exacerbations in patients with cystic fibrosis","volume":"48","author":"Turner","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"7","key":"10.1002\/14651858.CD009730.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thoraxjnl-2012-202342","article-title":"Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age","volume":"68","author":"Byrnes","year":"2013","journal-title":"Thorax"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009730.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1569-1993(09)60157-0","article-title":"Interim outcomes of a Pseudomonas aeruginosa (Pa) eradication protocol in young children in the Australian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) study","volume":"8","author":"Cheney","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009730.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"S118, Abstract","DOI":"10.1016\/S1569-1993(10)60452-3","article-title":"Trials, tribulations and triumphs of a cystic fibrosis study \u2013 a behind the scenes look at the workings of an international multi-centre study [abstract]","volume":"9","author":"Cheney","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD009730.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jcf.2014.12.007","article-title":"Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years","volume":"14","author":"Kidd","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD009730.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jpeds.2014.05.031","article-title":"Costs of bronchoalveolar lavage-directed therapy in the first 5 years of life for children with cystic fibrosis","volume":"165","author":"Moodie","year":"2014","journal-title":"Journal of Pediatrics"},{"issue":"Suppl 29","key":"10.1002\/14651858.CD009730.pub3-BIB0227|cit227","first-page":"317","article-title":"Australasian cystic fibrosis BAL study interim analysis [abstract]","volume":"41","author":"Wainwright","year":"2006","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 24","key":"10.1002\/14651858.CD009730.pub3-BIB0228|cit228","first-page":"300","article-title":"Early infection with pseudomonas aeruginosa can be cleared in young children with cystic fibrosis","volume":"34","author":"Wainwright","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"10","key":"10.1002\/14651858.CD009730.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/ppul.20885","article-title":"Safety of bronchoalveolar lavage in young children with cystic fibrosis","volume":"43","author":"Wainwright","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 34","key":"10.1002\/14651858.CD009730.pub3-BIB0230|cit230","first-page":"320","article-title":"Australasian CF bronchoalveolar lavage (ACFBAL) study: P. aeruginosa (PA) genotypes in pre-school CF children","volume":"46","author":"Wainwright","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD009730.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2011.954","article-title":"Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial","volume":"306","author":"Wainwright","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD009730.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2011.954","article-title":"Online supplement to 'Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial' [online]","volume":"306","author":"Wainwright","year":"2011","journal-title":"JAMA"},{"issue":"Suppl 19","key":"10.1002\/14651858.CD009730.pub3-BIB0233|cit233","first-page":"262","article-title":"Efficacy and safety of once daily tobramycin in treating acute respiratory exacerbations in adult patients","volume":"28","author":"Watson","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl","key":"10.1002\/14651858.CD009730.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0300-2977(99)90103-1","article-title":"Efficacy and safety of once daily tobramycin in treating acute respiratory exacerbations in adult patients","volume":"54","author":"Whitehead","year":"1999","journal-title":"Netherlands Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009730.pub3-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1183\/09031936.02.00221602","article-title":"Once-daily tobramycin in the treatment of adult patients with cystic fibrosis","volume":"19","author":"Whitehead","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00006454-199105000-00007","article-title":"Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients","volume":"10","author":"Winnie","year":"1991","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0237|cit237","unstructured":"Wolter JM Bowler SD McCormack JG Nolan PJ Home versus hospital therapy including intravenous antibiotics in cystic fibrosis 11th Annual Scientific Meeting of the Thoracic Society of Australia and New Zealand (TSANZ); 1994"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1183\/09031936.97.10040896","article-title":"Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects","volume":"10","author":"Wolter","year":"1997","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD009730.pub3-BIB0239|cit239","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0163-4453%2803%2900135-X","article-title":"A randomized trial of home vs hospital intravenous antibiotic therapy in adults with infectious diseases","volume":"48","author":"Wolter","year":"2004","journal-title":"Journal of Infection"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/thx.51.4.369","article-title":"Minimisation of aminoglycoside toxicity in patients with cystic fibrosis","volume":"51","author":"Wood","year":"1996","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0241|cit241","unstructured":"BEAT CF: pulmonary exacerbations treatment platform \u2013 backbone antibiotics domain trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12622000950763"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0242|cit242","unstructured":"BEAT CF: pulmonary exacerbations treatment platform \u2013 adjunct antibiotics domain trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12622001063707"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0243|cit243","unstructured":"Continuous infusion antipseudomonal beta-lactams for acute infective exacerbations in cystic fibrosis: a prospective randomised controlled trial trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12612000945820"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0244|cit244","unstructured":"Continuous infusion anti-pseudomonal beta-lactams for the treatment of acute, infective pulmonary exacerbations in cystic fibrosis: a prospective randomised controlled trial clinicaltrials.gov\/study\/NCT01667094"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0245|cit245","unstructured":"Standardizing treatments for pulmonary exacerbations \u2013 aminoglycoside study clinicaltrials.gov\/show\/NCT05548283"},{"issue":"9","key":"10.1002\/14651858.CD009730.pub3-BIB0246|cit246","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006682.pub6","article-title":"Duration of intravenous antibiotic therapy in people with cystic fibrosis","author":"Abbott","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD009730.pub3-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/thx.53.9.732","article-title":"Long term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis","volume":"53","author":"Ballmann","year":"1998","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD009730.pub3-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/thx.2006.067595","article-title":"Survey of acute renal failure in patients with cystic fibrosis in the UK","volume":"62","author":"Bertenshaw","year":"2007","journal-title":"Thorax"},{"issue":"9","key":"10.1002\/14651858.CD009730.pub3-BIB0249|cit249","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002009.pub7","article-title":"Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis","author":"Bhatt","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009730.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S1569-1993(11)60012-X","article-title":"Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials","volume":"10","author":"Bilton","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"153","key":"10.1002\/14651858.CD009730.pub3-BIB0251|cit251","doi-asserted-by":"publisher","first-page":"153ra130","DOI":"10.1126\/scitranslmed.3004458","article-title":"Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis","volume":"4","author":"Blainey","year":"2012","journal-title":"Science Translational Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009730.pub3-BIB0252|cit252","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1378\/chest.121.1.64","article-title":"Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis","volume":"121","author":"Britto","year":"2002","journal-title":"Chest"},{"issue":"9","key":"10.1002\/14651858.CD009730.pub3-BIB0253|cit253","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1164\/rccm.200407-989OC","article-title":"Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis","volume":"172","author":"Brody","year":"2005","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0254|cit254","unstructured":"Cystic Fibrosis Foundation Patient registry annual data report 2021 www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf"},{"issue":"8","key":"10.1002\/14651858.CD009730.pub3-BIB0255|cit255","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1136\/thx.2011.161117","article-title":"Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis","volume":"66","author":"Boer","year":"2011","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0256|cit256","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","article-title":"Treatment of lung infection in patients with cystic fibrosis: current and future strategies","volume":"11","author":"D\u00f6ring","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"issue":"9","key":"10.1002\/14651858.CD009730.pub3-BIB0258|cit258","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"10","key":"10.1002\/14651858.CD009730.pub3-BIB0259|cit259","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis","volume":"331","author":"Fuchs","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0260|cit260","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/thx.2006.060889","article-title":"Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis","volume":"62","author":"Goss","year":"2007","journal-title":"Thorax"},{"issue":"11","key":"10.1002\/14651858.CD009730.pub3-BIB0261|cit261","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010966.pub4","article-title":"Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)","author":"Heneghan","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7414","key":"10.1002\/14651858.CD009730.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0263|cit263","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0264|cit264","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"6","key":"10.1002\/14651858.CD009730.pub3-BIB0265|cit265","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002007.pub5","article-title":"Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis","author":"Holland","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD009730.pub3-BIB0266|cit266","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004197.pub6","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","author":"Langton Hewer","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0267|cit267","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"10","key":"10.1002\/14651858.CD009730.pub3-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","article-title":"Cystic Fibrosis Foundation Pulmonary Guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection","volume":"11","author":"Mogayzel","year":"2014","journal-title":"Annals of the American Thoracic Society"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0269|cit269","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"1","key":"10.1002\/14651858.CD009730.pub3-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0022-3476(77)80790-7","article-title":"Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin","volume":"90","author":"Parry","year":"1977","journal-title":"Journal of Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD009730.pub3-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0272|cit272","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2022"},{"issue":"12","key":"10.1002\/14651858.CD009730.pub3-BIB0273|cit273","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1086\/523280","article-title":"Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals","volume":"28","author":"Rogues","year":"2007","journal-title":"Infection Control and Hospital Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD009730.pub3-BIB0274|cit274","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0022-3476(98)70344-0","article-title":"The diagnosis of cystic fibrosis: a consensus statement","volume":"132","author":"Rosenstein","year":"1998","journal-title":"Journal of Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0276|cit276","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0277|cit277","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"5","key":"10.1002\/14651858.CD009730.pub3-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jcf.2011.05.002","article-title":"Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?","volume":"10","author":"Stressmann","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"10","key":"10.1002\/14651858.CD009730.pub3-BIB0279|cit279","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1136\/thoraxjnl-2011-200932","article-title":"Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience","volume":"67","author":"Stressmann","year":"2012","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0280|cit280","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/ppul.22652","article-title":"Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis","volume":"48","author":"Wagener","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009730.pub3-BIB0281|cit281","unstructured":"XYPLOT Creative Consulting for Research and Education 2010"},{"issue":"3","key":"10.1002\/14651858.CD009730.pub3-BIB0282|cit282","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009730","article-title":"Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis","author":"Hurley","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD009730.pub3-BIB0283|cit283","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009730.pub2","article-title":"Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis","author":"Hurley","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T22:49:20Z","timestamp":1751928560000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009730.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":283,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009730.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]}}}